3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
47
Triple Negative Breast Neoplasms
25
Ovarian Neoplasms
8
Neoplasm Metastasis
8
Melanoma
8
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
5
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Carcinoma, Merkel Cell
3
Lung Neoplasms
2
Kidney Neoplasms
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
Biopsy
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
durvalumab
×
Breast
×
Clear all
NCT05795101
2025-09-19
TRUDI
Dana-Farber Cancer Institute
Phase 2
Recruiting
63 enrolled